Who are Changchun marina's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, Topical Minoxidil（5%） to the scalp., (C) D-V14, Intravenous amiodarone(1), minoxidil + finasteride, Sevoflurane Inhalational Induction and Maintenance.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/changchun-marina.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Changchun marina — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changchun marina (Changchun marina) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-arrhythmic. Area: Cardiovascular.

marketed Anti-arrhythmic Potassium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Changchun marina (Changchun marina) — Nanjing NingQi Medicine Science and Technology Co., Ltd.. Changchun marina is a medication used to treat atrial fibrillation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Changchun marina TARGET	Changchun marina	Nanjing NingQi Medicine Science and Technology Co., Ltd.	marketed	Anti-arrhythmic	Potassium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
Topical Minoxidil（5%） to the scalp.	Topical Minoxidil（5%） to the scalp.	Southern Medical University, China	marketed	Potassium channel opener / topical vasodilator	ATP-sensitive potassium channels
(C) D-V14	(C) D-V14	National Taiwan University Hospital	marketed	Antiarrhythmic	Potassium channels
Intravenous amiodarone(1)	Intravenous amiodarone(1)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors
minoxidil + finasteride	minoxidil + finasteride	Beijing Dayspring Pharmaceutical Technology Co., Ltd	marketed	Combination antialopecia agent	Potassium channels (minoxidil); 5-alpha reductase type II (finasteride)
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	Abbott	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-arrhythmic class)

Nanjing NingQi Medicine Science and Technology Co., Ltd. · 1 drug in this class
University of British Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Changchun marina — Competitive Intelligence Brief. https://druglandscape.com/ci/changchun-marina. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab